Serina Therapeutics announces FDA clinical hold on SER-252 IND for advanced Parkinson's disease

Serina Therapeutics, Inc.

FDA placed clinical hold on SER-252 IND, requesting additional info on a commonly used excipient; not related to active drug or mechanism.
Serina expects formal clinical-hold letter within 30 days and will work expeditiously with FDA to address requests.
FDA previously indicated support for SER-252 development under 505(b)(2) NDA pathway; CEO remains confident in program.
SER-252 is Serina's lead program for advanced Parkinson's; Phase 1b trial designed as randomized, double-blind, placebo-controlled.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.